Jedd Wolchok

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service, Associate Director, Ludwig Center for Cancer Immunotherapy, Associate Member, Ludwig Cancer Research, Professor of Medicine, Weill Medical College of Cornell University, Memorial Sloan-Kettering Cancer Center. Scientific Co-Founder and Advisory Board Member of Tizona Therapeutics.

Dr. Wolchok is Chief of the Melanoma and Immunotherapeutics Service and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSKCC) with an expertise in the treatment of metastatic melanoma. His additional appointments include: Head of the Swim Across America – Ludwig Collaborative Laboratory; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI). He has helped establish MSKCC as a leader in the discovery and treatment of cancers with novel immunotherapies.

Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He is principal investigator of numerous ongoing clinical trials at MSKCC in the area of immunotherapy. He supervises an R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical mouse models. In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1-2 outpatient unit at MSKCC that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies.